pmid	doi	year	title	Hugo_Symbol
34115701	10.1097/RLU.0000000000003750	2022	Burkitt Lymphoma/Leukemia Presented on 68Ga-Pentixafor and 18F-FDG PET/CT.	CXCR4
34525196	10.1182/blood.2021013239	2022	CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication.	CXCR4
34651291	10.1007/s11307-021-01664-3	2022	CXCR4-Directed PET/CT with [<sup>68</sup>Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [<sup>18</sup>F]FDG PET/CT.	CXCR4
34990302	10.1080/21655979.2021.2017590	2022	Propofol induces the apoptosis of neural stem cells via microRNA-9-5p / chemokine CXC receptor 4 signaling pathway.	CXCR4
35020191	10.1111/bjh.18036	2022	Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline.	CXCR4
35037561	10.1080/10428194.2021.2020776	2022	Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.	CXCR4
35057088	10.3390/pharmaceutics14010192	2022	Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials.	CXCR4
35078860	10.1158/1078-0432.CCR-21-3284	2022	Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands.	CXCR4
35149375	10.1016/j.ctarc.2022.100527	2022	Current approach to Waldenström Macroglobulinemia.	CXCR4
35181615	NA	2022	Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications.	CXCR4
35241482	10.2967/jnumed.121.263693	2022	Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using <sup>68</sup>Ga-PentixaFor PET.	CXCR4
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	CXCR4
35339405	10.1016/j.clml.2022.02.005	2022	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.	CXCR4
35385630	NA	2022	Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?	CXCR4
35421785	10.1016/j.biopha.2022.112940	2022	A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4<sup>+</sup> lymphoma cells without toxicity in immunocompromised and immunocompetent mice.	CXCR4
35450208	10.1177/20406207221090886	2022	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.	CXCR4
35454017	10.3390/diagnostics12040969	2022	Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.	CXCR4
35510210	10.1177/20406207221093962	2022	Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.	CXCR4
35674738	10.1007/s00259-022-05849-y	2022	CXCR4-targeted theranostics in oncology.	CXCR4
35695746	10.1080/17474086.2022.2089110	2022	Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following <i>H. pylori</i> treatment?	CXCR4
35738903	10.2967/jnumed.122.264207	2022	C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.	CXCR4
35770040	10.2147/TCRM.S338655	2022	Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.	CXCR4
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	CXCR4
35794478	10.1038/s41586-022-04906-8	2022	Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.	CXCR4
35842683	10.1186/s13287-022-03011-x	2022	Prostaglandin E1 reduces apoptosis and improves the homing of mesenchymal stem cells in pulmonary arterial hypertension by regulating hypoxia-inducible factor 1 alpha.	CXCR4
35877223	10.3390/curroncol29070363	2022	Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation.	CXCR4
35884548	10.3390/cancers14143488	2022	Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review.	CXCR4
35954476	10.3390/cancers14153814	2022	The Role of [<sup>68</sup>Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review.	CXCR4
36030395	10.1111/ejh.13856	2022	A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience.	CXCR4
36048893	10.1093/ajcp/aqac104	2022	Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant.	CXCR4
32795528	10.1016/j.jid.2020.06.034	2021	Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12/CXCR4.	CXCR4
32810857	10.1159/000509286	2021	Current and Emerging Treatments for Waldenström Macroglobulinemia.	CXCR4
33131073	10.1111/exd.14228	2021	The role of Dipeptidyl Peptidase-4 in cutaneous disease.	CXCR4
33206936	10.1182/blood.2020005650	2021	Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.	CXCR4
33208624	10.1097/RLU.0000000000003404	2021	Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.	CXCR4
33253591	10.1021/acs.molpharmaceut.0c00785	2021	High-Contrast CXCR4-Targeted <sup>18</sup>F-PET Imaging Using a Potent and Selective Antagonist.	CXCR4
33391493	10.7150/thno.48620	2021	CXCR4 PET imaging of mantle cell lymphoma using [<sup>68</sup>Ga]Pentixafor: comparison with [<sup>18</sup>F]FDG-PET.	CXCR4
33579803	10.2967/jnumed.120.257279	2021	Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT.	CXCR4
33604348	10.3389/fmed.2021.609116	2021	YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial.	CXCR4
33612450	10.1016/j.transci.2021.103070	2021	First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients.	CXCR4
33660512	10.1021/acs.jmedchem.1c00066	2021	Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors.	CXCR4
33716502	10.2147/IJN.S289733	2021	Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4<sup>+</sup> Diffuse Large B-Cell Lymphoma Cells.	CXCR4
33735664	10.1016/j.neo.2021.02.002	2021	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.	CXCR4
33856274	10.1080/10428194.2021.1913150	2021	Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma.	CXCR4
33934404	10.1002/jcla.23784	2021	PCR array analysis identified hyperproliferation but not autophagy or apoptosis in fibrous epulis.	CXCR4
34083646	10.1038/s41598-021-91112-7	2021	DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity.	CXCR4
34093792	10.7150/jca.54952	2021	Aggregative Perivascular Tumor Cell Growth Pattern of Primary Central Nervous System Lymphomas Is Associated with Hypoxia-Related Endoplasmic Reticulum Stress.	CXCR4
34106998	10.1371/journal.ppat.1009618	2021	Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes.	CXCR4
34172595	10.1097/RLU.0000000000003760	2021	Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT.	CXCR4
34187383	10.1186/s12876-021-01844-z	2021	Tumor-to-tumor metastasis of diffuse large B cell lymphoma to gastric adenocarcinoma via CXCL12 (SDF-1)/CXCR4 axis: a case report.	CXCR4
34255748	10.1172/JCI143119	2021	Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia.	CXCR4
34269725	10.1097/RLU.0000000000003817	2021	CXCR4 Expression Demonstrated by 68Ga-Pentixafor PET/CT Imaging in a Case of Systemic Mastocytosis Mimicking Lymphoma.	CXCR4
34307181	10.3389/fonc.2021.710900	2021	Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes.	CXCR4
34363012	10.1038/s41375-021-01376-1	2021	CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.	CXCR4
34404617	10.1016/j.transci.2021.103240	2021	An innovation in stem cell harvesting: Heparin use.	CXCR4
34490994	10.1002/pbc.29319	2021	Single-center results reporting improved hematopoietic stem cell mobilization success in pediatric and young adult patients with solid tumors and lymphoma.	CXCR4
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	CXCR4
34583709	10.1186/s12943-021-01419-2	2021	Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.	CXCR4
34714390	10.1186/s13550-021-00852-0	2021	Semi-quantitative measurements of chemokine receptor 4-targeted <sup>68</sup>Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.	CXCR4
34793563	10.1371/journal.pone.0260186	2021	Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach.	CXCR4
34990523	10.4143/crt.2021.944	2021	Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia During R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma.	CXCR4
35087759	10.3389/fonc.2021.801124	2021	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.	CXCR4
31248974	10.3324/haematol.2018.211490	2020	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.	CXCR4
31260155	10.1002/jmri.26848	2020	MRI and PET/MRI in hematologic malignancies.	CXCR4
31471373	10.3324/haematol.2019.216218	2020	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.	CXCR4
31476465	10.1016/j.wneu.2019.08.140	2020	T140 Inhibits Apoptosis and Promotes Proliferation and Matrix Formation Through the SDF-1/CXC Receptor-4 Signaling Pathway in Endplate Chondrocytes of the Rat Intervertebral Discs.	CXCR4
31605845	10.1016/j.wneu.2019.09.158	2020	Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation.	CXCR4
31719683	10.1038/s41375-019-0628-0	2020	Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma.	CXCR4
31768009	10.1038/s41409-019-0756-1	2020	The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.	CXCR4
31902622	10.1016/j.pathol.2019.11.002	2020	A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.	CXCR4
31960730	10.1080/10428194.2020.1711901	2020	Waldenstrom's macroglobulinemia in the era of immunotherapy.	CXCR4
31980558	10.1136/jclinpath-2019-206282	2020	Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.	CXCR4
32083995	10.1200/JCO.19.02314	2020	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.	CXCR4
32296856	10.1007/s00117-020-00676-4	2020	[Hybrid imaging in lymphoma].	CXCR4
32332145	10.2967/jnumed.120.241703	2020	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma.	CXCR4
32370190	10.3390/cancers12051143	2020	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.	CXCR4
32373205	10.7150/thno.43231	2020	Selective delivery of T22-PE24-H6 to CXCR4<sup>+</sup> diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model.	CXCR4
32544428	10.1016/j.phrs.2020.105010	2020	CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent.	CXCR4
32694049	10.1016/j.clml.2020.05.003	2020	De Novo CD5<sup>+</sup> Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances.	CXCR4
32724470	10.7150/thno.45537	2020	A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.	CXCR4
32757068	10.1186/s13550-020-00681-7	2020	Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [<sup>68</sup>Ga]pentixafor in non-Hodgkin lymphoma: comparison to [<sup>18</sup>F]FDG.	CXCR4
32766282	10.3389/fmolb.2020.00164	2020	High-Throughput Screening of a Functional Human CXCL12-CXCR4 Signaling Axis in a Genetically Modified <i>S. cerevisiae</i>: Discovery of a Novel Up-Regulator of CXCR4 Activity.	CXCR4
32913458	10.7150/jca.48748	2020	Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients.	CXCR4
32955949	10.1080/14728214.2020.1822816	2020	Emerging drugs for the treatment of Waldenström macroglobulinemia.	CXCR4
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	CXCR4
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	CXCR4
33275726	10.1182/hematology.2020000121	2020	Management of Waldenström macroglobulinemia in 2020.	CXCR4
29777009	10.2967/jnumed.118.210997	2019	Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma.	CXCR4
29954928	10.3324/haematol.2017.180505	2019	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.	CXCR4
30290030	10.1002/stem.2912	2019	Microvesicles Secreted by Nitric Oxide-Primed Mesenchymal Stromal Cells Boost the Engraftment Potential of Hematopoietic Stem Cells.	CXCR4
30333224	10.1158/1078-0432.CCR-18-1047	2019	Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.	CXCR4
30623224	10.1007/s00347-018-0840-8	2019	[New molecular pathological strategies for malignant iris tumors].	CXCR4
30774774	10.18632/oncotarget.26588	2019	High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients.	CXCR4
30776910	10.1177/2040206619829382	2019	Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.	CXCR4
30836379	10.1038/s41586-019-1027-4	2019	HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.	CXCR4
30883140	10.1021/acs.molpharmaceut.9b00069	2019	Development and Evaluation of an <sup>18</sup>F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 Expression.	CXCR4
30904045	10.1016/j.amjms.2019.01.008	2019	CXCR4 and CCR7 Expression in Primary Nodal Diffuse Large B-Cell Lymphoma-A Clinical and Immunohistochemical Study.	CXCR4
30966844	10.1080/21505594.2019.1605803	2019	The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections.	CXCR4
30985424	10.1097/RLU.0000000000002574	2019	68Ga CXCR-4 PET/CT Imaging in an Atypical Case of Extramedullary Plasmacytoma Mimicking as Renal Cell Carcinoma.	CXCR4
31004184	10.1007/s00259-019-04322-7	2019	[<sup>68</sup>Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery.	CXCR4
31096215	10.1159/000497430	2019	C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges.	CXCR4
31101745	10.2967/jnumed.119.226134	2019	<sup>68</sup>Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to <sup>18</sup>F-FDG PET/CT.	CXCR4
31105032	10.1016/j.ebiom.2019.05.025	2019	LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML.	CXCR4
31106661	10.1080/15384101.2019.1617007	2019	Loss of β-arrestin-2 gene and possible functional consequences on Sezary Syndrome.	CXCR4
31229160	10.1016/j.hoc.2019.03.004	2019	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.	CXCR4
31281504	10.7150/thno.31032	2019	Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [<sup>68</sup>Ga]Ga-Pentixafor-PET/MRI.	CXCR4
31358475	10.1016/j.ebiom.2019.07.053	2019	Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.	CXCR4
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	CXCR4
31545614	10.1021/acs.molpharmaceut.9b00808	2019	[<sup>68</sup>Ga]Ga/[<sup>177</sup>Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4.	CXCR4
31554271	10.3390/ijms20194740	2019	The <i>CXCR4-CXCL12</i>-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro.	CXCR4
31557894	10.3390/cancers11101427	2019	FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma.	CXCR4
31591468	10.1038/s41375-019-0592-8	2019	What is new in the treatment of Waldenstrom macroglobulinemia?	CXCR4
31695539	10.2147/JBM.S183997	2019	Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.	CXCR4
28631842	10.1002/jca.21563	2018	UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.	CXCR4
28952842	10.1080/10428194.2017.1379077	2018	Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.	CXCR4
29272530	10.1093/molehr/gax067	2018	Formyl peptide receptor-2 is decreased in foetal growth restriction and contributes to placental dysfunction.	CXCR4
29435003	10.3892/ol.2017.7636	2018	Opposite response to hypoxia by breast cancer cells between cell proliferation and cell migration: A clue from microRNA expression profile.	CXCR4
29485974	10.1172/JCI97454	2018	Redirection to the bone marrow improves T cell persistence and antitumor functions.	CXCR4
29642081	10.1097/RLI.0000000000000469	2018	[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results.	CXCR4
29856685	10.1056/NEJMoa1802917	2018	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.	CXCR4
29903571	10.1016/j.cyto.2018.02.020	2018	Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.	CXCR4
29920526	10.1371/journal.pone.0198789	2018	CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.	CXCR4
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	CXCR4
30190015	10.1016/j.hoc.2018.05.007	2018	Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.	CXCR4
30194255	10.1182/blood-2018-04-845834	2018	Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.	CXCR4
30242208	10.1038/s41598-018-32634-5	2018	Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma.	CXCR4
30373149	10.3390/cancers10110402	2018	Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination.	CXCR4
27840426	10.1038/leu.2016.330	2017	Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.	CXCR4
27905003	10.1007/s12185-016-2156-2	2017	New agents in HSC mobilization.	CXCR4
28064239	10.1182/blood-2016-07-729954	2017	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.	CXCR4
28231592	10.1159/000455706	2017	CXCR4: A New Player in an Old Scene?	CXCR4
28280994	10.1007/s00277-017-2968-z	2017	Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.	CXCR4
28281555	10.1038/modpathol.2017.5	2017	NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.	CXCR4
28282510	10.1016/j.hemonc.2017.01.002	2017	CXCR4 (CD184) expression on stem cell harvest and CD34<sup>+</sup> cells post-transplant.	CXCR4
28331368	10.2147/CMAR.S94059	2017	New developments in the management of Waldenström macroglobulinemia.	CXCR4
28357672	10.1007/978-1-4939-6872-5_15	2017	Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.	CXCR4
28533307	10.1182/blood-2017-04-776740	2017	SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.	CXCR4
28577295	10.1186/s13550-017-0294-z	2017	Response assessment with the CXCR4-directed positron emission tomography tracer [<sup>68</sup>Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities.	CXCR4
28617062	10.1080/17474086.2017.1343661	2017	Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.	CXCR4
28646116	10.1182/blood-2016-10-747303	2017	Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.	CXCR4
28694325	10.1182/blood-2017-03-770982	2017	TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL.	CXCR4
28699226	10.1111/imm.12792	2017	Epstein-Barr virus (EBV) provides survival factors to EBV<sup>+</sup> diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV<sup>+</sup>  DLBCL.	CXCR4
28744319	10.7150/thno.19119	2017	[<sup>177</sup>Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.	CXCR4
28877839	10.3881/j.issn.1000-503X.2017.04.019	2017	Significances of MYD88<sup>L265P</sup> and CXCR4<sup>WHIM</sup> Mutations in Waldenstrom Macroglobulinemia.	CXCR4
28903575	10.14735/amko20172S81	2017	Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.	CXCR4
28916148	10.1016/j.ymeth.2017.09.002	2017	Chemokine receptor - Directed imaging and therapy.	CXCR4
29025291	10.1556/650.2017.30868	2017	[Waldenström's macroglobulinemia and its individualized therapy options].	CXCR4
29153094	10.1016/j.cancergen.2017.09.002	2017	Differences between chronic lymphocytic leukaemia and small lymphocytic lymphoma cells by proteomic profiling and SNP microarray analysis.	CXCR4
29156704	10.18632/oncotarget.18844	2017	ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration.	CXCR4
29222280	10.1182/asheducation-2017.1.365	2017	Toward personalized treatment in Waldenström macroglobulinemia.	CXCR4
29296751	10.1182/bloodadvances.2016003921	2017	A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.	CXCR4
29365396	10.3760/cma.j.issn.0253-2727.2017.12.006	2017	[Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].	CXCR4
29527563	10.1186/s41181-016-0020-6	2017	[<sup>64</sup>Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model.	CXCR4
26153511	10.1111/ejh.12626	2016	Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.	CXCR4
26303343	10.1159/000435769	2016	Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.	CXCR4
26350264	10.1158/1078-0432.CCR-15-0987	2016	ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.	CXCR4
26369824	10.2174/1568026615666150915120218	2016	Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.	CXCR4
26554889	10.1097/MOH.0000000000000200	2016	Plerixafor for stem cell mobilization: the current status.	CXCR4
26659815	10.1111/bjh.13897	2016	Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.	CXCR4
26885608	10.18632/oncotarget.7320	2016	Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.	CXCR4
26942591	10.1007/s11864-016-0391-7	2016	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.	CXCR4
26954567	10.1371/journal.pone.0150585	2016	Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.	CXCR4
26969772	10.1016/j.bjhh.2015.07.011	2016	Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review.	CXCR4
27090170	10.1016/j.blre.2016.02.003	2016	FDG-PET imaging in hematological malignancies.	CXCR4
27135782	10.1002/pbc.26035	2016	CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.	CXCR4
27268124	10.1016/j.clml.2016.04.014	2016	Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.	CXCR4
27297662	10.1038/ncomms11889	2016	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.	CXCR4
27307990	10.1186/s40364-016-0067-2	2016	The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines.	CXCR4
27374031	10.1016/j.medcli.2016.05.019	2016	[Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].	CXCR4
27544389	10.1007/s00432-016-2220-6	2016	Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin.	CXCR4
27598329	10.1080/17460441.2016.1233176	2016	Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.	CXCR4
27655427	10.1186/s13550-016-0227-2	2016	Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [(68)Ga]pentixafor.	CXCR4
27725861	NA	2016	Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811.	CXCR4
27799525	10.1073/pnas.1615258113	2016	Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice.	CXCR4
27825467	10.1016/j.beha.2016.08.021	2016	Future therapeutic options for patients with Waldenström macroglobulinemia.	CXCR4
27890075	10.1016/j.leukres.2016.10.008	2016	Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.	CXCR4
27905841	10.1089/apc.2016.0245	2016	Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population.	CXCR4
28056298	10.3760/cma.j.issn.0529-5807.2016.12.005	2016	[Significance of CXCL12/CXCR4 expression in T-lymphoblastic lymphoma/leukemia].	CXCR4
30042959	10.18383/j.tom.2016.00130	2016	First <sup>18</sup>F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo.	CXCR4
31360080	10.2147/BLCTT.S84157	2016	Waldenström macroglobulinemia: biology, genetics, and therapy.	CXCR4
25231113	10.1002/path.4446	2015	CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.	CXCR4
25232031	10.1158/1541-7786.MCR-14-0150	2015	Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.	CXCR4
25236359	10.1179/2295333714Y.0000000077	2015	Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium.	CXCR4
25504752	10.1158/1535-7163.MCT-14-0850	2015	Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.	CXCR4
25655610	10.1007/978-3-319-13150-4_7	2015	Biology, prognosis, and therapy of Waldenström Macroglobulinemia.	CXCR4
25679974	NA	2015	Waldenström macroglobulinemia.	CXCR4
25681335	10.4049/jimmunol.1402610	2015	Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.	CXCR4
25688243	10.3389/fimmu.2015.00012	2015	Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges.	CXCR4
25704881	10.18632/oncotarget.3343	2015	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.	CXCR4
25819228	10.1111/bjh.13361	2015	MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.	CXCR4
25825601	10.7150/thno.11251	2015	Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.	CXCR4
25853860	10.1371/journal.pone.0122338	2015	Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.	CXCR4
25878069	10.1093/glycob/cwv022	2015	Interference with the CXCL12/CXCR4 axis as potential antitumor strategy: superiority of a sulfated galactofucan from the brown alga Saccharina latissima and fucoidan over heparins.	CXCR4
25938000	10.1186/s40164-015-0004-3	2015	Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.	CXCR4
26138997	10.1586/17474086.2015.1061427	2015	Ibrutinib for the treatment of Waldenström macroglobulinemia.	CXCR4
26170971	10.3892/ol.2015.3182	2015	SGK3 (CISK) may induce tumor angiogenesis (Hypothesis).	CXCR4
26194765	10.1182/blood-2015-04-640805	2015	Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells.	CXCR4
26755907	10.5114/pdia.2015.48034	2015	Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides.	CXCR4
23781769	10.1111/trf.12265	2014	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.	CXCR4
23949965	10.1002/hon.2090	2014	Phenotype profiling of primary testicular diffuse large B-cell lymphomas.	CXCR4
24018164	10.1016/j.semcancer.2013.08.011	2014	The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.	CXCR4
24117899	10.1111/trf.12429	2014	Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.	CXCR4
24118008	10.1111/trf.12434	2014	Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.	CXCR4
24128272	10.1111/trf.12459	2014	Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.	CXCR4
24329982	10.1111/trf.12516	2014	High-dose methotrexate in the mobilization of hematopoietic stem cells for patients with non-Hodgkin's lymphoma: a twelve-year study in a single center.	CXCR4
24677543	10.1182/blood-2013-12-545954	2014	Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis?	CXCR4
24680978	10.1016/j.bbmt.2014.03.019	2014	Polymorphism of CD44 influences the efficacy of CD34(+) cells mobilization in patients with hematological malignancies.	CXCR4
24711662	10.1182/blood-2014-03-564583	2014	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.	CXCR4
24799524	10.1158/1078-0432.CCR-14-0154	2014	Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).	CXCR4
24859274	10.1371/journal.pone.0098194	2014	Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factor.	CXCR4
24917186	10.1186/1471-2407-14-418	2014	B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells.	CXCR4
25070183	10.3892/mmr.2014.2425	2014	Administration of a plasmid that expresses SDF-1α affects the oncogenic potential of mouse bcr-abl-transformed cells.	CXCR4
25378977	10.3904/kjim.2014.29.6.785	2014	Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.	CXCR4
25550696	10.4110/in.2014.14.6.296	2014	Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells.	CXCR4
22936065	10.1038/modpathol.2012.134	2013	Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma.	CXCR4
23213054	10.1158/1078-0432.CCR-12-2333	2013	BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.	CXCR4
23238991	10.1007/s10495-012-0787-1	2013	Snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles induce apoptosis and growth arrest in human prostate cancer cells.	CXCR4
23295736	10.1038/leu.2012.358	2013	U-2932: two clones in one cell line, a tool for the study of clonal evolution.	CXCR4
23405135	10.1371/journal.pone.0055324	2013	Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology.	CXCR4
23628037	10.7534/j.issn.1009-2137.2013.02.025	2013	[Expressions of VEGF and CXCR4 in diffuse large B cell lymphoma and their clinical significances].	CXCR4
23637121	10.1158/1078-0432.CCR-12-3015	2013	Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.	CXCR4
23698254	10.1097/CAD.0b013e328360cd8c	2013	Plerixafor and autologous stem cell transplantation: impressive result in a chemoresistant testicular cancer patient treated with high-dose chemotherapy.	CXCR4
23940282	10.1182/blood-2013-02-482125	2013	Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.	CXCR4
23943384	10.1007/s11912-013-0332-6	2013	Therapeutic options for adult T-cell leukemia/lymphoma.	CXCR4
24179472	10.1159/000354132	2013	Physiology and pharmacology of plerixafor.	CXCR4
24415962	10.1159/000354229	2013	Current clinical indications for plerixafor.	CXCR4
21740294	10.3109/10428194.2011.601698	2012	Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists.	CXCR4
21981351	10.1111/j.1537-2995.2011.03349.x	2012	Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.	CXCR4
21992403	10.1111/j.1600-0609.2011.01719.x	2012	Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.	CXCR4
22186993	10.1182/blood-2011-04-347518	2012	Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia.	CXCR4
22202080	10.2741/s288	2012	Optimizing stem cell collection through CXCR4 antagonists.	CXCR4
22231445	10.1038/onc.2011.604	2012	STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.	CXCR4
22264762	10.1016/j.bmc.2011.12.052	2012	Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression.	CXCR4
22304442	10.1111/j.1537-2995.2011.03525.x	2012	Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.	CXCR4
22420651	10.1186/1750-9378-7-6	2012	HIV Co-receptor usage in HIV-related non-hodgkin's lymphoma.	CXCR4
22465758	10.1016/j.transci.2012.03.011	2012	Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.	CXCR4
22508288	10.1002/hep.25790	2012	Recruitment mechanisms of primary and malignant B cells to the human liver.	CXCR4
22509798	10.1111/j.1365-2141.2012.09123.x	2012	A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential.	CXCR4
22722314	10.1038/bjc.2012.272	2012	PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.	CXCR4
22740445	10.1182/blood-2012-03-415380	2012	Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas.	CXCR4
22796644	10.1016/j.bbmt.2012.07.002	2012	Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield.	CXCR4
22808135	10.1371/journal.pone.0040332	2012	Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma.	CXCR4
23009155	10.1186/1750-1172-7-71	2012	Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry.	CXCR4
23170195	10.4084/MJHID.2012.066	2012	New strategies for stem cell mobilization.	CXCR4
23234751	NA	2012	[Hematopoietic cells raising with plerixafor in non-Hodgkin lymphoma].	CXCR4
23251606	10.1371/journal.pone.0051661	2012	Cellular and molecular mechanisms underlie the anti-tumor activities exerted by Walterinnesia aegyptia venom combined with silica nanoparticles against multiple myeloma cancer cell types.	CXCR4
20880037	10.1111/j.1537-2995.2010.02896.x	2011	Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.	CXCR4
20938660	10.1007/s00277-010-1098-7	2011	Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.	CXCR4
20951741	10.1016/j.imlet.2010.09.022	2011	New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas.	CXCR4
21210239	10.1007/s10014-010-0013-1	2011	CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target.	CXCR4
21474836	10.1177/1087057111403480	2011	Imaging-based assay for identification and characterization of inhibitors of CXCR4-tropic HIV-1 envelope-dependent cell-cell fusion.	CXCR4
21492180	10.1111/j.1537-2995.2011.03136.x	2011	Effectiveness and cost analysis of just-in-time salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.	CXCR4
21669033	10.3727/096368911X580536	2011	Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.	CXCR4
21672222	10.1186/1476-4598-10-73	2011	The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells.	CXCR4
21806478	10.1517/14712598.2011.601737	2011	Novel strategies for blood stem cell mobilization: special focus on plerixafor.	CXCR4
21816850	10.1095/biolreprod.111.091793	2011	Spermatogonial stem cell self-renewal requires ETV5-mediated downstream activation of Brachyury in mice.	CXCR4
21861545	10.2165/11206040-000000000-00000	2011	Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.	CXCR4
22174304	10.1182/blood-2011-10-386524	2011	Can we build a better allograft?	CXCR4
24198526	10.2147/SCCAA.S6713	2011	Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.	CXCR4
19483760	10.1038/bmt.2009.119	2010	Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.	CXCR4
19748593	10.1016/j.bbmt.2009.09.003	2010	A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.	CXCR4
19896878	10.1016/j.jfms.2009.09.008	2010	Differential CXCR4 expression and function in subpopulations of the feline lymphoma cell line 3201 susceptible to feline immunodeficiency virus.	CXCR4
19949101	10.4049/jimmunol.0901980	2010	gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.	CXCR4
20397073	10.1007/82_2010_26	2010	CXCR4 in clinical hematology.	CXCR4
20411999	10.1592/phco.30.5.485	2010	Plerixafor: a peripheral blood stem cell mobilizer.	CXCR4
20473162	10.1097/MOH.0b013e328338b7d5	2010	Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.	CXCR4
20530974	10.1159/000315736	2010	FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.	CXCR4
20685493	10.1016/j.clinthera.2010.05.007	2010	Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.	CXCR4
20689431	10.1097/CCO.0b013e32833d752c	2010	Recent advances of IMiDs in cancer therapy.	CXCR4
20826182	10.1016/j.pharmthera.2010.08.009	2010	Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.	CXCR4
20872671	10.1002/ijc.25236	2010	Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells.	CXCR4
20939442	NA	2010	Plerixafor. Only for certain patients when G-CSF stem cell mobilisation fails.	CXCR4
21098756	10.1345/aph.1P223	2010	Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.	CXCR4
21099212	10.1159/000321509	2010	Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer.	CXCR4
21106070	10.1186/1471-2407-10-644	2010	If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma.	CXCR4
21159639	10.1158/0008-5472.CAN-10-1943	2010	CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.	CXCR4
18488221	10.1007/s00262-008-0528-z	2009	Expression and function of T cell homing molecules in Hodgkin's lymphoma.	CXCR4
19135941	10.1016/j.bbmt.2008.10.018	2009	Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.	CXCR4
19161986	10.1016/j.bcp.2008.12.014	2009	The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).	CXCR4
19167685	10.1016/j.bbmt.2008.11.028	2009	Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.	CXCR4
19228923	10.1182/blood-2008-10-185827	2009	Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.	CXCR4
19242508	10.1038/jid.2009.45	2009	Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors.	CXCR4
19275275	10.2165/00003495-200969030-00007	2009	Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.	CXCR4
19308288	10.1593/neo.81508	2009	Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration.	CXCR4
19657116	10.1182/blood-2008-11-189308	2009	Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.	CXCR4
19720922	10.1200/JCO.2008.20.7209	2009	Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.	CXCR4
19834627	10.1358/dot.2009.45.7.1395292	2009	Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells.	CXCR4
19927352	10.1002/jcla.20346	2009	CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.	CXCR4
19929463	10.3109/14653240903121245	2009	A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.	CXCR4
21076551	10.1159/000235954	2009	Turning CD34 Non-Mobilizers into Mobilizers: A Case Report Involving Plerixafor (AMD3100).	CXCR4
21082960	10.1586/ehm.09.54	2009	Mobilization of hematopoietic stem cells into the peripheral blood.	CXCR4
18277033	10.2169/internalmedicine.47.0500	2008	Peripheral T-cell lymphoma following diffuse large B-cell lymphoma associated with celiac disease.	CXCR4
18374178	10.1016/S0076-6879(07)00427-2	2008	Rho GTPases and regulation of hematopoietic stem cell localization.	CXCR4
18561120	10.1002/path.2372	2008	Distinct signatures of B-cell homeostatic and activation-dependent chemokine receptors in the development and progression of extragastric MALT lymphomas.	CXCR4
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	CXCR4
18940680	10.1016/j.bbmt.2008.08.011	2008	A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.	CXCR4
17198877	10.1016/j.exphem.2006.09.006	2007	Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4.	CXCR4
17324009	10.2165/00126839-200708020-00006	2007	Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791.	CXCR4
17324341	10.3816/clm.2007.n.009	2007	AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.	CXCR4
17336267	10.1016/j.bbrc.2007.02.053	2007	Dynamic interplay between the neutral glycosphingolipid CD77/Gb3 and the therapeutic antibody target CD20 within the lipid bilayer of model B lymphoma cells.	CXCR4
17369141	10.1309/NUQHJ79BHWYD9TAF	2007	Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1.	CXCR4
17553309	NA	2007	[The role of stromal cell derived factor-1/CXCR4 biological axis in tumor metastasis of non-Hodgkin lymphoma].	CXCR4
17641901	10.1007/s00401-007-0258-x	2007	Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma.	CXCR4
17697366	10.1186/ar2210	2007	B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue.	CXCR4
17784839	10.1089/scd.2006.0087	2007	Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.	CXCR4
17875700	10.1158/0008-5472.CAN-06-4722	2007	Differential regulation of hypoxia-induced CXCR4 triggering during B-cell development and lymphomagenesis.	CXCR4
16118018	10.1016/j.leukres.2005.07.009	2006	Chemokine receptor expression and function in childhood acute lymphoblastic leukemia of B-lineage.	CXCR4
16204308	10.1182/blood-2005-04-1492	2006	Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV.	CXCR4
16476057	10.1111/j.1365-2567.2005.02311.x	2006	Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells.	CXCR4
16619289	10.1002/eji.200535799	2006	Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing.	CXCR4
16815309	10.1016/j.bcp.2006.05.010	2006	Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.	CXCR4
16863911	10.1016/j.exphem.2006.06.003	2006	The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.	CXCR4
16923552	10.1080/10428190600562112	2006	The SDF-1 G &gt; A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia.	CXCR4
17005036	10.1186/1742-4690-3-64	2006	Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias.	CXCR4
17049119	10.1111/j.1745-7254.2006.00415.x	2006	Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro.	CXCR4
17058243	10.1002/hep.21365	2006	Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence.	CXCR4
17071491	10.1080/10428190600775599	2006	Survey of chemokine receptor expression reveals frequent co-expression of skin-homing CCR4 and CCR10 in adult T-cell leukemia/lymphoma.	CXCR4
17079483	10.1158/0008-5472.CAN-06-1981	2006	Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma.	CXCR4
15454484	10.1182/blood-2004-03-0799	2005	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation.	CXCR4
15833868	10.1158/0008-5472.CAN-04-4280	2005	Construction of a minimal HIV-1 variant that selectively replicates in leukemic derived T-cell lines: towards a new virotherapy approach.	CXCR4
16018941	10.1016/j.urolonc.2005.02.004	2005	Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression.	CXCR4
16038794	10.1016/j.cellsig.2004.12.009	2005	Heterologous regulation of chemokine receptor signaling by the lipid phosphatase SHIP in lymphocytes.	CXCR4
16080846	NA	2005	[The expression and clinical significance of stromal cell-derived factor-1 and CXCR4 in acute leukemia and malignant lymphoma].	CXCR4
16178723	10.2174/1389557054867075	2005	Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.	CXCR4
16211229	NA	2005	Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression.	CXCR4
16269859	10.1159/000088410	2005	Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.	CXCR4
16373702	10.1158/1535-7163.MCT-05-0146	2005	Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures.	CXCR4
11157475	10.1182/blood.v97.3.608	2001	SHP2 and cbl participate in alpha-chemokine receptor CXCR4-mediated signaling pathways.	CXCR4
